Lineage Cell Therapeutics Inc (LCTX)

$0.88

-0.03

(-2.98%)▲

Live

Performance

  • $0.88
    $0.94
    $0.88
    downward going graph

    0.0%

    Downside

    Day's Volatility :6.38%

    Upside

    6.38%

    downward going graph
  • $0.77
    $1.61
    $0.88
    downward going graph

    12.9%

    Downside

    52 Weeks Volatility :52.39%

    Upside

    45.34%

    downward going graph

Returns

PeriodLineage Cell Therapeutics IncIndex (Russel 2000)
3 Months
-11.05%
0.0%
6 Months
-20.41%
0.0%
1 Year
-21.78%
0.0%
3 Years
-60.89%
-23.0%

Highlights

Market Capitalization
158.3M
Book Value
$0.36
Earnings Per Share (EPS)
-0.13
Wall Street Target Price
5.0
Profit Margin
0.0%
Operating Margin TTM
-416.69%
Return On Assets TTM
-12.86%
Return On Equity TTM
-35.04%
Revenue TTM
6.2M
Revenue Per Share TTM
0.03
Quarterly Revenue Growth YOY
-56.3%
Gross Profit TTM
14.0M
EBITDA
-21.4M
Diluted Eps TTM
-0.13
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.13
EPS Estimate Next Year
-0.15
EPS Estimate Current Quarter
-0.05
EPS Estimate Next Quarter
-0.05

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Lineage Cell Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
11
11
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 468.18%

Current $0.88
Target $5.00

Company Financials

FY18Y/Y Change
Revenue
1.4M
↓ 20.98%
Net Income
-46.0M
↑ 130.23%
Net Profit Margin
-3.2K%
↓ 2133.15%
FY19Y/Y Change
Revenue
1.5M
↑ 4.38%
Net Income
-11.8M
↓ 74.28%
Net Profit Margin
-800.2%
↑ 2447.68%
FY20Y/Y Change
Revenue
773.0K
↓ 47.7%
Net Income
-20.7M
↑ 74.9%
Net Profit Margin
-2.7K%
↓ 1875.74%
FY21Y/Y Change
Revenue
3.9M
↑ 404.01%
Net Income
-38.6M
↑ 86.43%
Net Profit Margin
-989.84%
↑ 1686.1%
FY22Y/Y Change
Revenue
14.7M
↑ 277.39%
Net Income
-26.4M
↓ 31.66%
Net Profit Margin
-179.24%
↑ 810.6%
FY23Y/Y Change
Revenue
8.9M
↓ 39.16%
Net Income
-21.5M
↓ 18.47%
Net Profit Margin
-240.2%
↓ 60.96%
Q1 FY23Q/Q Change
Revenue
2.4M
↑ 24.6%
Net Income
-4.4M
↓ 33.19%
Net Profit Margin
-184.58%
↑ 159.65%
Q2 FY23Q/Q Change
Revenue
3.2M
↑ 35.16%
Net Income
-5.2M
↑ 18.73%
Net Profit Margin
-162.14%
↑ 22.44%
Q3 FY23Q/Q Change
Revenue
1.2M
↓ 61.36%
Net Income
-7.1M
↑ 35.97%
Net Profit Margin
-570.63%
↓ 408.49%
Q4 FY23Q/Q Change
Revenue
2.1M
↑ 67.58%
Net Income
-4.8M
↓ 32.84%
Net Profit Margin
-228.69%
↑ 341.94%
Q1 FY24Q/Q Change
Revenue
1.4M
↓ 30.84%
Net Income
-6.5M
↑ 37.01%
Net Profit Margin
-453.05%
↓ 224.36%
Q2 FY24Q/Q Change
Revenue
1.4M
↓ 2.49%
Net Income
-5.8M
↓ 11.95%
Net Profit Margin
-409.09%
↑ 43.96%
FY18Y/Y Change
Total Assets
101.7M
↓ 41.32%
Total Liabilities
9.4M
↑ 4.86%
FY19Y/Y Change
Total Assets
125.5M
↑ 23.43%
Total Liabilities
14.2M
↑ 51.17%
FY20Y/Y Change
Total Assets
107.9M
↓ 13.97%
Total Liabilities
12.8M
↓ 9.9%
FY21Y/Y Change
Total Assets
174.5M
↑ 61.69%
Total Liabilities
83.6M
↑ 552.37%
FY22Y/Y Change
Total Assets
123.7M
↓ 29.15%
Total Liabilities
51.7M
↓ 38.16%
FY23Y/Y Change
Total Assets
101.0M
↓ 18.31%
Total Liabilities
39.0M
↓ 24.61%
Q1 FY23Q/Q Change
Total Assets
113.2M
↓ 8.46%
Total Liabilities
44.2M
↓ 14.57%
Q2 FY23Q/Q Change
Total Assets
111.7M
↓ 1.34%
Total Liabilities
40.4M
↓ 8.51%
Q3 FY23Q/Q Change
Total Assets
106.2M
↓ 4.96%
Total Liabilities
39.5M
↓ 2.32%
Q4 FY23Q/Q Change
Total Assets
101.0M
↓ 4.84%
Total Liabilities
39.0M
↓ 1.26%
Q1 FY24Q/Q Change
Total Assets
108.5M
↑ 7.39%
Total Liabilities
37.5M
↓ 3.85%
Q2 FY24Q/Q Change
Total Assets
102.8M
↓ 5.24%
Total Liabilities
35.9M
↓ 4.18%
FY18Y/Y Change
Operating Cash Flow
-30.9M
↑ 1.2%
Investing Cash Flow
11.8M
↓ 215.56%
Financing Cash Flow
5.8M
↓ 89.58%
FY19Y/Y Change
Operating Cash Flow
-31.9M
↑ 3.45%
Investing Cash Flow
17.0M
↑ 43.51%
Financing Cash Flow
617.0K
↓ 89.31%
FY20Y/Y Change
Operating Cash Flow
-19.8M
↓ 38.17%
Investing Cash Flow
13.0M
↓ 23.11%
Financing Cash Flow
29.9M
↑ 4740.36%
FY21Y/Y Change
Operating Cash Flow
-23.6M
↑ 19.28%
Investing Cash Flow
9.7M
↓ 25.26%
Financing Cash Flow
36.9M
↑ 23.66%
FY22Y/Y Change
Operating Cash Flow
1.1M
↓ 104.49%
Investing Cash Flow
-46.2M
↓ 573.67%
Financing Cash Flow
1.6M
↓ 95.58%
Q1 FY23Q/Q Change
Operating Cash Flow
-11.2M
↑ 35.4%
Investing Cash Flow
15.4M
↓ 402.35%
Financing Cash Flow
1000.0
↓ 99.18%
Q2 FY23Q/Q Change
Operating Cash Flow
-6.3M
↓ 44.24%
Investing Cash Flow
19.2M
↑ 24.2%
Financing Cash Flow
5.6M
↑ 562700.0%

Technicals Summary

Sell

Neutral

Buy

Lineage Cell Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc
-3.77%
-20.41%
-21.78%
-60.89%
-6.45%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc
NA
NA
NA
-0.13
-0.35
-0.13
NA
0.36
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc
Buy
$158.3M
-6.45%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Lineage Cell Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 2.08M → 1.40M (in $), with an average decrease of 16.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -6.54M → -5.76M (in $), with an average increase of 13.6% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 107.3%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 105.7%

Company Information

biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

Organization
Lineage Cell Therapeutics Inc
Employees
68
CEO
Mr. Brian M. Culley M.A., M.B.A.
Industry
Health Technology

Discover More

FAQs